Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera Transcript

· seekingalpha.com

Silence Therapeutics plc (SLN) Discusses Top-Line Results From SANRECO Phase II Trial of Divesiran in Polycythemia Vera August 10, 2026 8:00 AM EDTCompany...

Presentation

Good morning. I would like to welcome you to the Silence Therapeutics conference call to discuss top-line results from the Phase II SANRECO study....


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI